Quick Answer
Seres Therapeutics, Inc. reported Earnings Per Share Diluted of $0.64 per share for the year ending 2025.
- This data is from Seres Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 12, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2020: $0.36 (loss) per share | Q2 2021: $0.53 (loss) per share | Q3 2021: $0.72 per share | Q1 2022: $0.61 (loss) per share | Q2 2022: $0.70 (loss) per share | Q3 2022: $0.49 (loss) per share | Q1 2023: $0.57 (loss) per share | Q2 2023: $0.36 per share | Q3 2023: $0.37 (loss) per share | Q1 2024: $5.49 (loss) per share | Q2 2024: $4.34 (loss) per share | Q3 2024: $11.63 per share | Q1 2025: $3.75 per share | Q2 2025: $2.27 (loss) per share | Q3 2025: $0.94 per share.
- Over the full 6 years of available data (2020 to 2025), Seres Therapeutics, Inc.'s Earnings Per Share Diluted has grown by 157.1%.
- Historical annual values: Fiscal year 2025: $0.64 per share | Fiscal year 2024: $0.00 per share | Fiscal year 2023: $17.77 (loss) per share | Fiscal year 2022: $2.31 (loss) per share | Fiscal year 2021: $0.72 (loss) per share | Fiscal year 2020: $1.12 (loss) per share.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: